Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 May;8(5):1018-26.
doi: 10.1111/j.1538-7836.2010.03792.x. Epub 2010 Feb 2.

Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population

Affiliations
Comparative Study

Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population

S A Lubitz et al. J Thromb Haemost. 2010 May.

Abstract

Summary background: Gene-based warfarin dosing algorithms have largely been developed in homogeneous populations, and their generalizability has not been established.

Objectives: We sought to assess the performance of published algorithms in a racially diverse and multiethnic sample, and determine if additional clinical variables or genetic variants associated with dose could enhance algorithm performance.

Patients and methods: In 145 compliant patients on warfarin with a goal international normalized ratio (INR) of 2-3, stable, therapeutic doses were compared with predicted doses using 12 reported algorithms that incorporated CYP2C9 and VKORC1 variants. Additional covariates tested with each model included race, concurrent medications, medications known to interact with warfarin and previously described CYP4F2, CALU and GGCX variants.

Results: The mean patient age was 67 +/- 14 years; 90 (62%) were male. Eighty-two (57%) were Caucasian, 28 (19%) African-American, 20 (14%) Hispanic and 15 (10%) Asian. The median warfarin dose was 35 mg per week (interquartile range 23-53 mg per week). Gene-based dosing algorithms explained 37-55% of the variation in warfarin dose requirements. Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.

Conclusions: Existing gene-based dosing algorithms explained between approximately one-third and one-half of the variability in warfarin dose requirements in this racially and ethnically diverse cohort. Additional clinical and recently described genetic variants associated with warfarin dose did not enhance prediction in our patient population.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Conflict of Interests

The authors state that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Therapeutic warfarin dose according to CYP2C9, VKORC1, CYP4F2, CALU and GGCX genotype. Weekly therapeutic warfarin doses were compared across genotypes. The boxes display the interquartile range of warfarin doses. Whiskers represent observed doses beyond this range with values less than or equal to 1.5 times the interquartile range. The median dose is indicated by the solid black bar. The number of individuals with each genotype is displayed in parenthesis.
Fig. 2
Fig. 2
Therapeutic warfarin dose according to race. Weekly therapeutic warfarin doses were compared across races. The boxes display the inter-quartile range of warfarin doses. Whiskers represent observed doses beyond this range with values less than or equal to 1.5 times the interquartile range. The median dose is indicated by the solid black bar.

References

    1. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167:1414–9. doi: 10.1001/archinte.167.13.1414. - DOI - PubMed
    1. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129:1155–66. doi: 10.1378/chest.129.5.1155. - DOI - PubMed
    1. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296:1858–66. doi: 10.1001/jama.296.15.1858. - DOI - PubMed
    1. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003;41:1633–52. - PubMed
    1. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285–93. doi: 10.1056/NEJMoa044503. - DOI - PubMed

Publication types